Crystal structure of mouse MD-1 with endogenous phospholipid bound in its cavity

Journal of Molecular Biology

Volumn 400, Issue 4, 2010, Pages 838-846

  Harada, Hitomi ^a   Ohto, Umeharu ^a   Satow, Yoshinori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Crystal structure; Glycoprotein; LPS; MD 1; MD 2 related lipid recognition protein

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN MD 1; GLYCOPROTEIN MD 2; OLIGOMER; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; COMPARATIVE STUDY; CRYSTAL STRUCTURE; ELECTRON; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL;

IVA; TETRA;

EID: 77954384339     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.05.063     Document Type: Article

References (30)

1. Miyake K., Shimazu R., Kondo J., Niki T., Akashi S., Ogata H., et al. Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J. Immunol. 1998, 161:1348-1353.
2. Inohara N., Nunez G. ML-a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem. Sci. 2002, 27:219-221.
3. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
4. Gay N.J., Gangloff M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 2007, 76:141-165.
5. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
6. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 1999, 189:1777-1782.
7. Miyake K., Yamashita Y., Hitoshi Y., Takatsu K., Kimoto M. Murine B-cell proliferation and protection from apoptosis with an antibody against a 105-kDa molecule-unresponsiveness of X-linked immunodeficient B-cells. J. Exp. Med. 1994, 180:1217-1224.
8. Miyake K., Yamashita Y., Ogata M., Sudo T., Kimoto M. RP105, a novel B-cell surface-molecule implicated in B-cell activation, is a member of the leucine-rich repeat protein family. J. Immunol. 1995, 154:3333-3340.
9. Nagai Y., Shimazu R., Ogata H., Akashi S., Sudo K., Yamasaki H., et al. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 2002, 99:1699-1705.
10. Ogata H., Su I., Miyake K., Nagai Y., Akashi S., Mecklenbrauker I., et al. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J. Exp. Med. 2000, 192:23-29.
11. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. 2005, 6:571-578.
12. Koarada S., Tada Y., Ushiyama O., Morito F., Suzuki N., Ohta A., et al. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2593-2600.
13. Ohto U., Fukase K., Miyake K., Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007, 316:1632-1634.
14. Kim H.M., Park B.S., Kim J.I., Kim S.E., Lee J., Oh S.C., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007, 130:906-917.
15. Visintin A., Latz E., Monks B.G., Espevik T., Golenbock D.T. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 2003, 278:48313-48320.
16. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
17. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTALW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
18. Ulmer A.J., Heine H., Feist W., Kusumoto S., Kusama T., Brade H., et al. Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partial structures. Infect. Immun. 1992, 60:3309-3314.
19. Kusumoto S., Fukase K., Fukase Y., Kataoka M., Yoshizaki H., Sato K., et al. Structural basis for endotoxic and antagonistic activities: investigation with novel synthetic lipid A analogs. J. Endotoxin Res. 2003, 9:361-366.
20. Means T.K., Golenbock D.T., Fenton M.J. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 2000, 11:219-232.
21. Viriyakosol S., Tobias P.S., Kitchens R.L., Kirkland T.N. MD-2 binds to bacterial lipopolysaccharide. J. Biol. Chem. 2001, 276:38044-38051.
22. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
23. Vonrhein C., Blanc E., Roversi P., Bricogne G. Automated structure solution with autoSHARP. Methods Mol. Biol. 2007, 364:215-230.
24. Collaborative Computational Project, No.4 The CCP4 Suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50:760-763.
25. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:2126-2132.
26. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53:240-255.
27. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
28. Laskowski R.A., Macarthur M.W., Moss D.S., Thornton J.M. PROCHECK-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
29. Liang J., Edelsbrunner H., Woodward C. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci. 1998, 7:1884-1897.
30. DeLano W.L. The PyMOL molecular graphics system 2008, DeLano Scientific LLC, Palo Alto, CA. http://www.pymol.org.